Mechanisms and Potential Treatment Options of Heart Failure in Patients With Multiple Myeloma
Open Access
- 26 June 2021
- journal article
- research article
- Published by Springer Nature in Cureus
- Vol. 13 (6) , e15943
Abstract
Multiple myeloma is a pathology of plasma cells, with one of the most common side effects of its treatment is heart failure. In addition, cardiac amyloidosis could cause heart failure by itself. Even though mechanisms of cardiac amyloidosis are known, and they involve lysosomal dysfunction, reactive oxygen species (ROS) accumulation, and infiltrative effect by fibrils, there is no specific agent that could protect from these effects. While the molecular mechanism of doxorubicin cardiotoxicity via topoisomerase II β is established, the only FDA-approved agent for treatment is dexrazoxane. Liposomal doxorubicin can potentially improve response and decrease the development of heart failure due to microscopic liposomes that can accumulate and penetrate only tumor vasculature. Supplements that enhance mitochondrial biogenesis are also shown to improve doxorubicin-induced cardiotoxicity. Other agents, such as JR-311, ICRF-193, and ursolic acid, could potentially become new treatment options. Proteasome inhibitors, novel agents, have significantly improved survival rates among multiple myeloma patients. They act on a proteasome system that is highly active in cardiomyocytes and activates various molecular cascades in malignant cells, as well as in the heart, through nuclear factor kappa B (NF-kB), endoplasmic reticulum (ER), calcineurin-nuclear factor of activated T-cells (NFAT), and adenosine monophosphate-activated protein kinase (AMPKa)/autophagy pathways. Metformin, apremilast, and rutin have shown positive results in animal studies and may become a promising therapy as cardioprotective agents. This article aims to highlight the main molecular mechanisms of heart failure among patients with multiple myeloma and potential treatment options to facilitate the development and research of new preventive strategies. Hence, this will have a positive impact on life expectancy in patients with multiple myeloma.Keywords
This publication has 71 references indexed in Scilit:
- Identification of the molecular basis of doxorubicin-induced cardiotoxicityNature Medicine, 2012
- Current perspectives on cardiac amyloidosisAmerican Journal of Physiology-Heart and Circulatory Physiology, 2012
- Echocardiographic Evaluation of Systolic and Diastolic Function in Patients With Cardiac AmyloidosisThe American Journal of Cardiology, 2011
- Multiple Facets of NF-κB in the HeartCirculation Research, 2011
- Proteasome functional insufficiency activates the calcineurin–NFAT pathway in cardiomyocytes and promotes maladaptive remodelling of stressed mouse heartsCardiovascular Research, 2010
- Cardiotoxicity of the Anticancer Therapeutic Agent BortezomibThe American Journal of Pathology, 2010
- The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothingNucleic Acids Research, 2008
- Protective Effects of Carvedilol Against Anthracycline-Induced CardiomyopathyJACC, 2006
- Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cellsBlood, 2006
- Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapyJACC, 2000